Clinical and demographic data for study patients with rheumatoid arthritis (RA) stratified by atherothrombotic manifestation (ATM). Data are mean ± SD or n (%).
| Variable | All Patients | Patients without ATM | Patients with ATM |
|---|---|---|---|
| Age, yrs | 60.6 ± 13.2 | 58.0 ± 13.2 | 68.9 ± 9.2*** |
| Age at onset, yrs | 45.4 ± 15.5 | 43.7 ± 14.9 | 51.1 ± 16.2*** |
| Disease duration, yrs | 15.5 ± 12.6 | 14.6 ± 12.0 | 18.3 ± 14.1** |
| Women | 498 (73.1) | 395 (75.7)** | 103 (64.8) |
| Rheumatoid factor | 617/676 (91.3) | 470/518 (90.7) | 147/158 (93.0) |
| ACPA | 522/645 (80.9) | 407/504 (80.8) | 115/141 (81.6) |
| HLA-SE (0401/0404/0408) | 426/661 (64.4) | 329/511 (64.4) | 97/150 (64.7) |
| Nodules | 217/678 (32.0) | 151/519 (29.1) | 66/159 (41.5)** |
| Erosions | 543/666 (81.5) | 414/513 (80.7) | 129/153 (84.3) |
| Accumulated disease activity* | 4.58 ± 0.97 | 4.56 ± 0.97 | 4.66 ± 0.98 |
| Ever smoked | 325/674 (48.2) | 246/520 (47.3) | 79/154 (51.3) |
| Previous ATM† | 83/681 (12.3) | — | 84/159 (52.8) |
| Hypertension | 256/679 (37.7) | 172/520 (33.1) | 84/159 (52.8)*** |
| Diabetes | 45/677 (6.6) | 25/519 (4.8) | 20/158 (12.7)** |
| DMARD, ever | 622/678 (91.7) | 479/520 (92.1) | 143/158 (90.5) |
| Methotrexate, ever | 411/678 (60.6) | 330/520 (63.5)** | 81/158 (51.3) |
| Steroids, ever | 389/677 (57.5) | 270/518 (52.1) | 119/159 (74.8)*** |
| Lipid-lowering drugs (statins) | 14/681 (2.1) | 4/522 (0.8) | 10/159 (6.3)*** |
| Anti-TNF therapy | 27/681 (4.0) | 27/522 (5.2)** | 0/159 (0) |
↵* Calculated according to Baecklund, et al35.
↵** p < 0.01,
↵*** p < 0.001.
↵† ATM defined as myocardial infarction, angina pectoris with intervention, stroke/transient ischemic attack, and deep-vein thrombosis/pulmonary embolism after onset of RA. ACPA: anticitrullinated protein antibodies; HLA-SE: HLA shared-epitope; DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor.